EXPRESSION OF THE MDR3 GENE IN PROLYMPHOCYTIC LEUKEMIA - ASSOCIATION WITH CYCLOSPORINE-A-INDUCED INCREASE IN DRUG ACCUMULATION

被引:57
作者
NOOTER, K
SONNEVELD, P
JANSSEN, A
OOSTRUM, R
BOERSMA, T
HERWEIJER, H
VALERIO, D
HAGEMEIJER, A
BAAS, F
机构
[1] DANIEL DENHOED CANC CTR, ROTTERDAM, NETHERLANDS
[2] ERASMUS UNIV, DEPT GENET, 3000 DR ROTTERDAM, NETHERLANDS
[3] NETHERLANDS CANC INST, 1066 CX AMSTERDAM, NETHERLANDS
[4] ERASMUS UNIV, HOSP DIJKZIGT, DEPT HEMATOL, ROTTERDAM, NETHERLANDS
关键词
D O I
10.1002/ijc.2910450409
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Typical multidrug resistance in human and animal cell lines is caused by overactivity of an unidirectional transmembrane drug efflux pump, encoded by the MDR genes, called mdr genes in mice and humans and pgp genes in hamsters. In humans, two mdr genes, mdr1 and mdr3, with approximately 80% nucleotide homology, have been identified. There is increasing evidence that overexpression of the mdr1 gene plays a role in resistance to anticancer agents in specific tumor types. However, currently no data are available on a possible role for mdr3 in drug resistance. Here we report high levels of expression of mdr3 gene sequences in leukemic cells from 6 out of 6 patients with prolymphocytic leukemia (PLL). No mdr1 expression was detected in 5 out of 6 of these samples, whereas a low level of mdr1 expression was found in a sample from one PLL patient in the course of transformation to non‐Hodgkin's lymphoma. Except for this patient, all other PLL cases studied had not received prior chemotherapy. In vitro drug uptake studies showed that daunorubicin accumulation in PLL cells was increased by cyclosporin A. Since cyclosporin A is an inhibitor of the mdr1‐encoded P‐glycoprotein drug pump, these data suggest that in PLL cells mdr3 also codes for a drug efflux pump. Our findings could partly explain the primary refractoriness of PLL to chemotherapy. Copyright © 1990 Wiley‐Liss, Inc., A Wiley Company
引用
收藏
页码:626 / 631
页数:6
相关论文
共 42 条
[21]  
MOSCOW JA, 1989, CANCER RES, V49, P1422
[22]  
NAITO M, 1989, CANCER RES, V49, P1452
[23]   EFFECT OF CYCLOSPORINE-A ON DAUNORUBICIN ACCUMULATION IN MULTIDRUG-RESISTANT P388 LEUKEMIA-CELLS MEASURED BY REAL-TIME FLOW-CYTOMETRY [J].
NOOTER, K ;
OOSTRUM, R ;
JONKER, R ;
VANDEKKEN, H ;
STOKDIJK, W ;
VANDENENGH, G .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1989, 23 (05) :296-300
[24]  
NOOTER K, 1983, CANCER RES, V43, P5126
[25]  
NOOTER K, 1990, IN PRESS INT J CANCE
[26]   ISOLATION OF HUMAN MDR-DNA SEQUENCES AMPLIFIED IN MULTIDRUG-RESISTANT KB CARCINOMA-CELLS [J].
RONINSON, IB ;
CHIN, JE ;
CHOI, K ;
GROS, P ;
HOUSMAN, DE ;
FOJO, A ;
SHEN, D ;
GOTTESMAN, MM ;
PASTAN, I .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1986, 83 (12) :4538-4542
[27]   CYCLOSPORINE-A CORRECTS DAUNORUBICIN RESISTANCE IN EHRLICH ASCITES-CARCINOMA [J].
SLATER, LM ;
SWEET, P ;
STUPECKY, M ;
WETZEL, MW ;
GUPTA, S .
BRITISH JOURNAL OF CANCER, 1986, 54 (02) :235-238
[28]   DIFFERENCES IN UPTAKE OF ADRIAMYCIN AND DAUNOMYCIN BY NORMAL BM CELLS AND ACUTE-LEUKEMIA CELLS DETERMINED BY FLOW-CYTOMETRY [J].
SONNEVELD, P ;
VANDENENGH, GJ .
LEUKEMIA RESEARCH, 1981, 5 (03) :251-257
[29]  
TAYLOR HG, 1982, CANCER-AM CANCER SOC, V48, P1524, DOI 10.1002/1097-0142(19820415)49:8<1524::AID-CNCR2820490803>3.0.CO
[30]  
2-U